盐酸埃克替尼治疗晚期非小细胞肺癌的临床观察

目的:观察盐酸埃克替尼治疗晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）的疗效、安全性及其影响因素。方法:回顾性分析云南省肿瘤医院2013年11月-2016年2月收治的接受盐酸埃克替尼治疗的晚期NSCLC患者56例，对患者疗效、生存期及毒副反应进行评价。结果:56例患者均可评价疗效，客观有效率（objective response rate,ORR）为30.4%，疾病控制率（disease control rate，DCR）为83.9%，中位无进展生存期（progression free survival，PFS）为9个月。腺癌患者的DCR、PFS均优于鳞癌患者（P＜0.05）。12例患者进行EGFR基因检测，均为突变阳性，EGFR突变患者的ORR为58.3%，DCR为100%，PFS为9个月。EGFR突变患者的ORR优于EGFR状态未知患者（P＜0.05）。毒副反应主要为轻度的皮肤毒性和腹泻。结论:盐酸埃克替尼是治疗晚期NSCLC的有效药物，毒副反应较轻，腺癌患者能获得较好的疗效，EGFR突变患者的疗效更好。

Clinical observation of Icotinib hydrochloride treatment for patients with advanced non -small cell lung cancer

Objective:To evaluate the efficacy and side effect of Icotinib hydrochloride in the treatment of patients with advanced non - small cell lung cancer(NSCLC),and explore the association of clinical characteristics with effi-cacy and survival. Methods:The clinical data of 56 NSCLC patients in Yunnan Province Tumor Hospital from November 2013 to Feburary 2016 were retrospectively analysed. Results:The overall objective response rate(ORR)was30. 4% , disease control rate(DCR)was 83. 9% ,median progression free survival(PFS)time was 9 months. DCR and PFS in patients with pulmonary adenocarcinoma were superior than patients with squamous lung cancer(P ﹤ 0. 05). 12 pa-tients with EGFR analysis,were all positive for EGFR mutation. Among these 12 patients,ORR was 58. 3% ,DCR was 100% ,median PFS time was 9 months. EGFR mutation carriers had higher ORR than patients without EGFR informa-tion(P ﹤ 0. 05). The most common adverse events were mild rash and diarrhea. Conclusion:Icotinib hydrochloride is effective and tolerated for patients with advanced NSCLC,especially in EGFR mutation carriers,and also has effect in pulmonary adenocarcinoma patients.